INTRODUCTION
An estimated 4.7% of the incident dialysis population are recipients with failing kidney transplants (RFKTs) (Ojo et al. 1998) . With steady expansion in numbers of patients with endstage kidney disease receiving kidney transplants as their renal replacement therapy modality, and attenuated improvements in long-term graft survival, it is inevitable the cohort of kidney transplant patients with failing or failed allografts will increase in the future (Lamb et al. 2011) . Managing this distinct cohort requires special considerations dependent upon whether the allograft is failing or failed. In the context of failing kidney allografts, attention is required to managing the complications of declining renal function, tailored immunosuppression to optimize allograft longevity (dependent upon the underlying aetiology of decline) and appropriate planning for continued renal replacement therapy in the event of allograft failure (of which re-transplantation is the preferred option if deemed suitable). However, transplant-specific evidence-base is lacking and non-transplant aspects of care are translated from general nephrology. For patients with failed allografts who return to dialysis as their modality of renal replacement therapy, there is a lack of evidence with regards to appropriate management of immunosuppression or benefits of transplant nephrectomy.
LITERATURE REVIEW
A literature review reinforces a significant lack of evidence-base and lack of clarity as to whether kidney transplant recipients with poor graft function receive suboptimal care. This is particularly in the context of the timing of dialysis re-initiation and the management of the complications of renal failure, suggesting sub-optimal care (Gill et al. 2002b) . Messa et al. (2008) report heterogeneous outcomes for patients starting dialysis after graft failure, reflecting the lack of published consensus on this issue. This translates into disparate management guidelines for transplant clinicians in how to deal with failing or failed kidney transplants (Pham et al. 2015) . These are important issues to investigate as failed kidney transplants are associated with an increased risk of cardiovascular and infection-related death for RFKTs as allograft function declines (Fuquay & Teitelbaum 2012) . In addition, once the kidney allograft has failed, there is a significant mortality risk for kidney transplant recipients once they return to dialysis as their form of renal replacement therapy (Gill et al. 2002a) .
In light of the sparse published literature, the British Transplantation Society (BTS) published guidelines for the management of patients with failing kidney grafts and suggested the use of dedicated LCTCs to provide tailored care from both a transplant and low clearance perspective (British Transplantation Society 2014). However, it is unclear how many transplant centres have developed such dedicated clinics for patients with failing kidney grafts versus incorporating CKD-related care into their general transplant clinics. In addition, there is no evidence to suggest a LCTC provides any better care for patients with failing kidney transplants compared to regular general transplant clinics.
Therefore, the aim of this study was to compare the management of two groups of matched patients with failing kidney transplant populations at a large transplant centre; one cohort managed in a dedicated LCTC versus another cohort managed in a general transplant clinic.
METHODOLOGY

STUDY DESIGN AND POPULATION
We undertook a retrospective analysis of patients with failing kidney transplants between two clinics; a dedicated LCTC versus a general transplant clinic. The dedicated LCTC developed from one of the two general transplant clinics occurring on a weekly basis, with transfer of care for patients with an estimated glomerular filtration rate (eGFR) below 20 ml/min from that particular general transplant clinic. Thereby two cohorts of patients with failing kidney transplants have evolved over the last few years; those managed in the dedicated LCTC versus those remaining in the other general transplant clinic. This formed our basis for comparative analysis to determine the effectiveness of a dedicated LCTC.
Patients in either clinic with two consecutive follow-up visits between the dates of January and July 2016 were selected. We excluded any patients who had concomitant clinic visits in both clinics during the study period. We also excluded any patients reviewed for the first time in the LCTC after kidney transplant failure and already commenced on dialysis. We undertook a cross-sectional analysis of all patients over a sixmonth period between January 2016 and July 2016 and undertook a longitudinal analysis of all patients with follow-up data up to December 2017 to ascertain an up-to-date status for each patient.
STUDY APPROVAL
STUDY VARIABLES
Data were electronically extracted from clinic lists for every study recruit, with manual data linkage to electronic patient records to ensure a full dataset for analysis.
We compared the following outcomes in our cross sectional analysis between the two clinic cohorts, based on the recommended BTS guidelines on the management of patients with failing kidney grafts (8) and the electronic chronic kidney disease guidelines from the Renal Association available online at https://renal.org/information-resources/ the-uk-eckd-guide/.
1. Documented status of hepatitis B vaccination 2. Documented discussions regarding renal replacement therapy (including discussions on re-transplantation and preferred dialysis modality) 3. Defined transplant status (e.g. active, under work up, suspended or deemed not medically fit) 4. Blood pressure below recommended levels (<130/80 mmHg) 5. Haemoglobin at recommended levels (10-12 g/dl) 6. Bicarbonate above recommended levels: >20 mmol/l) 7. Phosphate at recommended levels (0.9-1.5 mmol/l) 8. Parathyroid hormones (PTH) had been checked in the last 12 months.
For our longitudinal analysis, we sought to determine the up-todate status of patients from the original cohort with reference to the following: IMMUNOSUPPRESSION PROTOCOL All patients abide with the same de novo immunosuppression protocol with minimization of tacrolimus exposure, in line with the SYMPHONY protocol (Ekberg et al. 2007) . Induction therapy was with basiliximab (20 mg Â2) and methylprednisolone (500 mg). Maintenance therapy included tacrolimus (target 12-hour trough level 5-8 ng/l), mycophenolate mofetil (MMF, 2 g daily with tapering to 1 g daily after six months) and maintenance corticosteroids. Biopsies were indication-based in the context of transplant dysfunction (categorised as !20% creatinine rise or new-onset proteinuria). Biopsy data were classified in accordance to latest Banff criteria (Haas et al. 2018) . Episodes of acute cellular rejection were treated with a bolus of corticosteroids, with T-cell depletion therapy for steroidresistant rejection. Antibody-mediated rejection was treated with antibody removal by plasmapheresis AE intravenous immunoglobulin. Viral serology (e.g. polyoma virus) and/or anti-HLA antibodies was checked by indication-basis based upon transplant dysfunction.
However, maintenance immunosuppression may have been tailored in the context of a failing kidney allograft but this, in light of a paucity of evidence-base guidelines to follow, would have been undertaken on an individual basis by the transplant clinician in charge.
STATISTICAL ANALYSIS
Univariate comparisons were carried out with chi-squared tests for categorical data and Mann-Whitney U tests for nonparametric continuous data. Time to event outcomes were analysed using Cox Regression Models. All-cause graft failure was taken as the time from transplantation to graft nephrectomy or return to dialysis, whichever was earlier, or death of the patient with a functioning graft. Survival of the patient was defined as the time from transplantation until death. Follow-up analysis of the entire transplant study cohort included all data up to December 2017. Additional analysis after propensity score matching was undertaken by assigning a propensity score using a logistic regression model using the following covariates (age, male gender, diabetes, hypertension, known cardiovascular disease, white ethnicity, transplant <1 year and deceased-donor). To ensure good matches, a caliper (maximum allowable difference between two participants) of 0.2 was defined. A p-value < 0.05 was considered statistically significant. All statistical analysis was undertaken using IBM SPSS 24 (IBM Corp. Armonk, NY).
RESULTS
BASELINE DEMOGRAPHICS
Data for 141 patients were analysed (60 in LCTC and 81 in general transplant clinic). Figure 1) . A more detailed breakdown of these discussions is presented in Table 2 . Table 3 and Figure 1 summarise the biochemical and clinical 6-month outcomes between the cohorts. Overall no significant differences were noted in the number of patients with results outside the BTS recommended levels when comparing LCTC versus general transplant clinic recipients on clinical and biochemical parameters.
BIOCHEMICAL AND CLINICAL OUTCOMES
1-YEAR FOLLOW-UP
We undertook a 1-year follow-up analysis to see the status of patients in the original cross-sectional analysis (see Tables 3 and 4) . More patients seen in the LCTC had lost their kidney allograft and were currently back on dialysis or re-transplanted compared to the general transplant clinic (HR: 2.09, 95%CI: 1.17-3.72, p ¼ 0.013).
For those with graft failure from the LCTC, 80.6% were on haemodialysis, 2.8% were on peritoneal dialysis and 16.7% had been re-transplanted. For those with graft failure under follow-up in the general transplant clinic, 68.0% were on haemodialysis, 12.0% were on peritoneal dialysis and 20.0% had been re-transplanted. (2014) recommend patients with failing kidney allografts should have ready access to low-clearance multi-disciplinary teams (level 2C evidence) but does not distinguish whether this is best initiated through a dedicated LCTC. To our knowledge, this is the first study to have assessed the benefits of a dedicated LCTC and demonstrates improved counselling and preparation for kidney transplant failure.
Our results suggest that LCTCs are effective in ensuring discussion regarding dialysis and re-transplantation but have similar efficacy in the management of biochemical and clinical parameters. This is significant as poor graft function in patients with failing kidney transplants has been associated with an increased risk of mortality, predominantly from cardiovascular and infective causes (Weiner et al. 2012) . Therefore, managing the determinants of cardiovascular disease (including blood pressure, anaemia, hyper-phosphate, and bicarbonate) in patients with failing kidneys is critically important and this appears to be performed to a similar standard in both clinic services.
However, preparation for allograft failure was better (or certainly better documented) among recipients under the care of the LCTC. This is important as the transition between kidney allograft failure and commencement of dialysis is associated with significant morbidity and mortality. For example, Gill et al. (2002a) analysed data from the United States Renal Data System (USRDS) for patients who initiated dialysis after kidney transplant failure. Among 4,741 patients who initiated dialysis after kidney transplant failure, followed up for a median of 15-month, the risk of mortality was significant at 21% with the majority of deaths were secondary to cardiovascular (36%) and infection (17%) causes (unknown in 22%). In addition, reinitiating dialysis after losing a kidney transplant can be a very traumatic episode for patients and a specialist clinic focussed on discussing renal replacement therapy options could be beneficial psychologically.
A qualitative, longitudinal study highlighted the devastating impact kidney transplant failure has on patients, with feelings of shock, grief, guilt, loss, anger and depression (Gill & Lowes 2014) . This compares with kidney transplant rejection and failure being the two biggest concerns cited by kidney transplant recipients with working allografts regarding their biggest posttransplant worries (Howell et al. 2012) . Therefore, the Table 4 : Cox regression models of patient/graft survival.
All statistics are relative to the general transplant clinic group. Survival outcomes were analysed using Cox regression models, and the reported statistics are hazard ratios. Values in brackets are 95% percent confidence intervals. Bold p-values are significant at p < 0.05 10.7 (9.1-11.7) 11.5 (9.9-12.4) 0.061 Bicarbonate (mmol/l) 22.1 (19.5-24.8) 22.8 (20.7-25.4 advantage of a transplant clinic specially designed to discuss the likelihood of their kidney transplant failure could be beneficial to patients. While we did not undertake patient satisfactory surveys as part of this audit, this would be useful to ascertain whether the patient experience is improved in the LCTC versus the general transplant clinics for patients with a failing kidney transplant.
The other issue is whether focussed care in a LCTC is associated with improved kidney transplant longevity but this question cannot be specifically answered with our data. The 1-year outcome data demonstrated greater kidney transplant failure in the LCTC which requires discussion. One explanation for this observation is that the LCTC is also utilised for many recipients who are booked in with imminent allograft loss for discussions regarding RRT. This is reflected in the greater proportion of patients with difficult early (<1-year) kidney transplants, with a trend towards more delayed graft function, which would be at high risk of failure. In addition, there were some differences in baseline characteristic (e.g. more non-white recipients in the LCTC) that may impact upon more graft attrition rates. It would be interesting to compare long-term maintenance patients in both clinics, with matched profiles, for their long-term outcomes to determine if there is any advantage with LCTC from that perspective.
It could be speculated that the continuity of care offered by our LCTC, being overseen by a single transplant nephrologist, facilitates improved care. For example, there is evidence in primary care that continuity of care in general practice is linked to improved outcomes such as prevention of secondary care admissions (Barker et al. 2017) and continuity of care is also associated with heightened patient satisfaction in systematic reviews of the literature (Adler et al. 2010) . However, we must be clear that our data do not demonstrate any clinical benefit on graft attrition rates, and in fact suggest worse graft loss rates, and therefore further clarification of such service is warranted.
To ensure a like-for-like comparison of patients between clinics, we excluded any patients seen in the LCTC for the first time after kidney transplant failure. These patients were often booked in (as solitary visits if not already under review) to counsel regarding their kidney transplant failure, discussion regarding immunosuppression tapering and long-term planning prior to discharge to the dialysis clinic. This is an important group of patients who have limited evidence-base to guide their longterm management (Pham et al. 2015) , with a lack of consensus guidance with regards to appropriate timing of dialysis initiation, immunosuppression management and transplant nephrectomy. While the LTC has been designed to improve the care of RFKTs, to ensure a smooth transition to dialysis or retransplantation, the optimal management of recipients with failed kidney transplants is equally important.
There are several limitations with our analysis which should be appreciated in the correct interpretation of our data. This is a small single-centre study and more data are warranted before more firm conclusions can be made regarding long-term clinical benefits of a LCTC. This is a heterogeneous group of patients, with different pre-transplant co-morbidities and post-transplant events, that limit a direct comparison of outcomes. The six-month period chosen, or auditing may not be representative of our clinic cohorts and further analysis of larger cohorts, with longer follow-up, is warranted. While comparison of clinical and biochemical parameters was objectively made from data extraction of electronic patient records, evidence for renal replacement therapy discussions was on the basis of documentation on patient letters. While clear documentation is advantageous for patient care, this approach may ignore conversations and plans that may be in progress without clear documentation and under-estimate renal replacement therapy planning. Hospitalisation episodes were restricted to our centre only and we would miss any hospitalisation events regionally or nationally. The LCTC is currently overseen by a single transplant nephrologist and it is difficult to distinguish any comparative differences to the LCTC service from the individual (or continuity of care from a single individual) per se.
Patient feedback was missing from this analysis and ascertaining patient-reported outcome measures would be important to evaluate the merit of a LCTC service from the patient perspective (Basch 2017). Patient satisfaction surveys from both low clearance and general transplant clinic would be useful to collect to determine differences in patient feedback for both clinics and this will be the subject of further work. Finally, the aim of this study does not fit with the available data that is present. Specifically, we are comparing the difference in performance between two different typology of structures, however we are only looking at one example of each structure. Ideally, we would include data from greater number of clinics. However, given the limited number of LCTC in the United Kingdom, this was not possible.
IMPLICATIONS FOR PRACTICE
In summary, our data suggest the implementation of dedicated LCTCs in the management of patients with failing kidney transplants is beneficial for renal replacement planning. We suggest the management of RFKTs may be improved with the development of dedicated LCTCs to focus attention on key aspects of care including renal replacement therapy planning and counselling for impending kidney transplant failure.
CONCLUSION
Further work with a matched-cohort analysis, greater numbers and longer duration is warranted to determine whether dedicated clinics promote kidney transplant longevity.
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